Treatment of Gastric Cancer
Publish place: 17th Congress of the Iranian Society for Oncology and Hematology and the Annual Cancer Nursing Conference
Publish Year: 1397
نوع سند: مقاله کنفرانسی
زبان: English
View: 321
نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد
- Certificate
- من نویسنده این مقاله هستم
این Paper در بخشهای موضوعی زیر دسته بندی شده است:
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
ISMOH17_060
تاریخ نمایه سازی: 10 اردیبهشت 1398
Abstract:
The Authors focused on the current surgical treatment of resectable gastric cancer, and significance of peri- and post-operative chemo or chemoradiation. Gastric cancer is the 4th most commonly diagnosed cancer and the second leading cause of cancer death worldwide. Surgery remains the only curative therapy, while perioperative and adjuvant chemotherapy, as well as chemoradiation, can improve outcome of resectable gastric cancer with extended lymph node dissection. Morethan halfof radicallyresected gastric cancer patients relapse locally or with distant metastases, or receive thediagnosis ofgastric cancer when tumor is disseminated; therefore, median survival rarely exceeds 12 mo, and 5-years survival is less than 10%. Cisplatin and fluoropyrimidine-based chemotherapy, with addition of trastuzumab in human epidermal growth factor receptor positive patients, is the widely used treatment in stage IV patients fit for chemotherapy. Recent evidence supports the use of second-line chemotherapy after progression in patientswith good performance status
Authors
Behjat Kalantari M.D
Assistant Professor of Hematology Oncology School of Medicine, Kerman University of Medical Sciences, Kerman, Iran